Extractas Bioscience (formerly Tasmanian Alkaloids)
HQ AU45% share
pharmaceutical · input
Naloxone API (Opioid Overdose Antidote)
Semi-synthetic opioid antagonist derived from thebaine/oripavine; active ingredient in Narcan (intranasal spray) and injectable naloxone for opioid overdose reversal. Listed on WHO Essential Medicines list. Demand surged >400% during the fentanyl overdose crisis (2018-present). Manufactured from the same opium alkaloid feedstock as the opioids it reverses.
0
Source countries
3
Companies
1
Goods affected
0
Claims on record
What depends on it
Goods that need this input
1 essential American goods rely on naloxone api (opioid overdose antidote) somewhere upstream in their supply chain.
Who makes it
Supplier companies
3 companies produce naloxone api (opioid overdose antidote).
Emergent BioSolutions
HQ US40% share
Maker of branded Narcan (intranasal naloxone), now OTC.
Sun Pharmaceutical Industries Ltd.
HQ IN
Indian pharmaceutical company (NSE: SUNPHARMA, HQ Mumbai; ~₹600B revenue); world's fourth-largest specialty generic pharmaceutical company and India's largest pharma company by market cap. Sun Pharma manufactures salbutamol sulfate API and finished albuterol inhalers (pMDI and nebulizer solution) at multiple Indian manufacturing sites, supplying US and global generic markets through its Taro Pharmaceutical US subsidiary. Sun Pharma was founded in 1983 by Dilip Shanghvi, who started with just five pharmaceutical products and a single employee; today Sun Pharma employs 36,000 people and operates 43 manufacturing sites globally. Sun Pharma's founder Dilip Shanghvi is now one of India's wealthiest individuals — his journey from a $1M startup to a $30B market cap company in 40 years is one of the defining business stories of India's pharmaceutical sector rise.